University of Leeds
leeds.ac.ukTotal trials
202
Active
29
Phase 3
10
Total enrollment
7,796,979
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 19 of 19 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Ixazomib, thalidomide, & dexamethasone (ITD) re-induction | — | — | — | — | — | 1 | |
| Conventional autologous stem cell transplant | — | — | — | — | — | 1 | |
| Augmented autologous stem cell transplant | — | — | — | — | — | 1 | |
| ITD consolidation and ixazomib maintenance vs. No further therapy | — | — | — | — | — | 1 | |
| Cyclophosphamide | — | — | — | — | — | 5 | |
| Dexamethasone | — | — | — | — | — | 3 | |
| Lenalidomide | — | — | — | — | — | 2 | |
| Cefuroxime | — | — | — | — | — | 1 | |
| Bortezomib | — | — | — | — | — | 1 | |
| Daratumumab | — | — | — | — | — | 1 | |
| Melphalan | — | — | — | — | — | 1 | |
| Filgrastim | — | — | — | — | — | 1 | |
| Digoxin 0.125 MG | — | — | — | — | — | 1 | |
| Pomalidomide | — | — | — | — | — | 1 | |
| Olaparib Oral Tablet [Lynparza] | — | — | — | — | — | 1 | |
| AZD1390 | — | — | — | — | — | 1 | |
| Ceralasertib | — | — | — | — | — | 1 | |
| AZD5305 | — | — | — | — | — | 1 | |
| Durvalumab | — | — | — | — | — | 1 |
Next readouts
- 2022-12
- 2025-05-01
- 2025-10-01
- 2026-03
- 2026-03
- 2028-08-28
Top conditions
- Multiple Myeloma8
- Chronic Heart Failure8
- Rheumatoid Arthritis7
- Acute Myocardial Infarction6
- Cancer6
- Obesity5
- Healthy5
- Heart Failure5
Frequently asked questions about University of Leeds
- How many clinical trials does University of Leeds have on ClinicalTrials.gov?
- University of Leeds is listed as the lead sponsor on 202 clinical trials in ClinicalTrials.gov, 29 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Leeds's trials are in Phase 3?
- 10 of University of Leeds's trials are in Phase 3, spread across 19 active drug programs.
- What therapeutic areas does University of Leeds focus on?
- University of Leeds's most-studied conditions on ClinicalTrials.gov are Multiple Myeloma, Chronic Heart Failure, Rheumatoid Arthritis, Acute Myocardial Infarction, Cancer.
- When are University of Leeds's next clinical trial readouts?
- University of Leeds has 6 upcoming primary-completion readouts tracked here; the soonest is “Pomalidomide in Relapsed and Refractory Multiple Myeloma (RRMM)”, expected around 2022-12.